Production and characterization of a high-affinity nanobody against human endoglin

Hybridoma

Volumn 27, Issue 5, 2008, Pages 353-360

  Ahmadvand, Davoud ^a   Rasaee, Mohammad J ^a   Rahbarizadeh, Fatemeh ^a   Mohammadi, Mohammad ^b  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b SHAHID CHAMRAN UNIVERSITY OF AHVAZ   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANTIBODY ISOLATION; ANTIBODY PRODUCTION; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE LIBRARY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, CD; CAMELS; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; PEPTIDE LIBRARY; RECEPTORS, CELL SURFACE;

CAMELIDAE;

EID: 54249167046     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2008.0014     Document Type: Article

References (39)

1. Holliger P, and Hudson PJ: Engineered antibody fragments and the rise of single domains. Nat Biotech 2005;23(9):1126-1136.
2. Bremers AJ, and Parmiani G: Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol 2000;34(1):1-25.
3. Waldmann TA: Immunotherapy: past, present and future. Nat Med 2003;9(3):269-277.
4. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Bajyana Songa E, Bendahman N, and Hamers R: Naturally occurring antibodies devoid of light chains. Nature 1993;363:446-448.
5. Revets H, De Baetselier P, and Muyldermans S: Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther 2005;5(1):111-124.
6. Gibbs WW: Nanobodies. Sci Am 2005;293(2):78-83.
7. Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S, and Revets H: Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 2004;64(8):2853-2857.
8. Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, de Haard HJ, and van Bergen en Henegouwen PM: Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies. Cancer Immunol Immunother 2007; 56(3):303-317.
9. Khosravi Shahi P, and Fern†ndez Pineda I: Tumoral angiogenesis: review of the literature. Cancer Invest 2008;26(1):104-108.
10. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1(1):27-31.
11. Thorpe PE, and Burrows FJ: Antibody-directed targeting of the vasculature of solid tumors Breast Cancer Res Treat 1995;36(2):237-251.
12. Westphal JR, Willems HW, Schalkwijk CJ, Ruiter DJ, and de Waal RM: A new 180-kDa dermal endothelial cell activation antigen: in vitro and in situ characteristics. J Invest Dermatol 1993;100(1):27-34.
13. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES, and Thorpe PE: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995;1(12):1623-1634.
14. Miller DW, Graulich W, Karges B, Stahl S, Ernst M, Ramaswamy A, Sedlacek HH, MÅller R, and Adamkiewicz J: Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 1999;81(4):568-572.
15. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N, Inui K, and Wada H: Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001;7(11):3410-3415.
16. Fonsatti E, Jekunen AP, Kairemo KJ, Coral S, Snellman M, Nicotra MR, Natali PG, Altomonte M, and Maio M: Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 2000; 6(5):2037-2043.
17. Bredow S, Lewin M, Hofmann B, Marecos E, and Weissleder R: Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer 2000;36(5):675-681.
18. Tabata M, Kondo M, Haruta Y, and Seon BK: Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125) I-labeled anti-endoglin monoclonal antibodies. Int J Cancer 1999;82(5):737-742.
19. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, and Seon BK: Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999;5(2):371-382.
20. Seon BK, Matsuno F, Haruta Y, Kondo M, and Barcos M: Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 1997;3(7):1031-1044.
21. Li C, Guo B, Bernabeu C, and Kumar S: Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105. Microsc Res Tech 2001;52(4):437-449.
22. Van der Linden R, de Geus B, Stok W, Bos W, van Wassenaar D, Verrips T, and Frenken L: Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama. J Immunol Meth 2000;240:185-195.
23. Andris-Widhopf J, Radar C, Steinberger P, Fuller R, and Barbas CF III: Methods for the generation of chicken monoclonal antibody fragments by phage display. J Immunol Meth 2000;242:159-181.
24. Harrison JL, Williams SC, Winter G, and Nissim A: Screening of phage antibody libraries. Meth Enzymol 1996;267:83-109.
25. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
26. Rahbarizadeh F, Rasaee MJ, Forouzandeh M, and Allameh AA: Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris. Mol Immunol 2006;43(5):426-435.
27. Bradford MM: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;7:248-254.
28. Beatty JD, Beatty BG, and Vlahos WG: Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Meth 1987;100:173-179.
29. Nuttal SD, Irving RA, and Hudson PJ: Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents. Curr Pharmaceut Biotech 2000;1:253-263.
30. Harmsen MM, and De Haard HJ: Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 2007;77(1):13-22.
31. Roovers RC, van Dongen GA, and en Henegouwen PM: Nanobodies in therapeutic applications. Curr Opin Mol Ther 2007;9(4):327-335.
32. Bazl MR, Rasaee MJ, Foruzandeh M, Rahimpour A, Kiani J, Rahbarizadeh F, Alirezapour B, and Mohammadi M: Production of chimeric recombinant single domain antibody-green fluorescent fusion protein in Chinese hamster ovary cells. Hybridoma 2007;26(1):1-9.
33. Omidfar K, Rasaee MJ, Modjtahedi H, Forouzandeh M, Taghikhani M, and Golmakani N: Production of a novel camel single-domain antibody specific for the type III mutant EGFR. Tumour Biol 2004;25(5-6):296-305.
34. Mohammadi M, Rasaee MJ, Rajabibazl M, Paknejad M, Zare M, and Mohammadzadeh S: Epitope mapping of PR81 anti-MUC1 monoclonal antibody following PEPSCAN and phage display techniques. Hybridoma 2007;26(4):223-230.
35. Haruta Y, and Seon BK: Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci USA 1986;83(20):7898-7902.
36. Völkel T, Hölig P, Merdan T, Müller R, and Kontermann RE: Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta 2004:27;1663(1-2):158-166.
37. Völkel T, Müller R, and Kontermann RE: Isolation of endothelial cell-specific human antibodies from a novel fully synthetic scFv library. Biochem Biophys Res Commun 2004;317(2):515-521.
38. Corteze Netto G, Birlem Bleil C, Hilbig A, and Barbosa Coutinho LM: Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas. Neuropathology 2008;28(1):17-23.
39. Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000;21(3):505-515.